Graft Versus Host Disease: Epidemiology Forecast to 2028

2020-01-31
Price :
Published : Jan-2020
No. of Pages : 92
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Graft-Versus-Host Disease: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.3.1 US
3.3.2 5EU
3.3.3 Japan
3.4 Forecast Methodology
3.4.1 Sources Used
3.4.2 Sources Not Used
3.4.3 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for GvHD (2018-2028)
3.5.1 Incident Cases of First Allogeneic HSCT
3.5.2 Incident Cases of aGvHD in First Allogeneic HSCT
3.5.3 Incident Cases of cGvHD in First Allogeneic HSCT
3.5.4 Age-Specific Incident Cases of aGvHD and cGvHD
3.5.5 Diagnosed Incident Cases of aGvHD by Grade
3.5.6 Diagnosed Incident Cases of cGvHD by Severity
3.5.7 100-Day Mortality in Diagnosed Incident Cases of aGvHD
3.5.8 One-Year Mortality in Diagnosed Incident Cases of cGvHD
3.5.9 Three-Year Diagnosed Prevalent Cases of aGvHD
3.5.10 Three-Year Diagnosed Prevalent Cases of cGvHD
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
4.5 Disclaimer

List of Tables
Table 1: Summary of Newly Added Data Types and Countries
Table 2: Summary of Updated Data Types
Table 3: Risk Factors for GvHD

List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of GvHD in Diagnosed Incident Cases of First Allogeneic HSCT Cases, All Ages, Both Sexes, 2018 and 2028
Figure 2: 7MM, Diagnosed Incidence of aGvHD per 100 Diagnosed Incident First Allogeneic HSCT Cases, All Ages, Both Sexes, 2018
Figure 3: 7MM, Diagnosed Incidence of cGvHD per 100 Diagnosed Incident First Allogeneic HSCT Cases, All Ages, Both Sexes, 2018
Figure 4: Case Flow Map of aGvHD and cGvHD
Figure 5: Sources Used for First Allogeneic HSCT
Figure 6: Sources Used for aGvHD and cGvHD in First Allogeneic HSCT
Figure 7: Sources Used for aGvHD Grades
Figure 8: Sources Used for cGvHD Severity
Figure 9: Sources Used for 100-Day Mortality of aGvHD and One-Year Mortality of cGvHD
Figure 10: Sources Used for Three-Year Diagnosed Prevalent Cases of aGvHD and cGvHD
Figure 11: 7MM, Diagnosed Incident Cases of First Allogeneic HSCT Cases, Men and Women, All Ages, 2018
Figure 12: 7MM, Diagnosed Incident Cases of aGvHD in First Allogeneic HSCT Cases, Men and Women, All Ages, 2018
Figure 13: 7MM, Diagnosed Incident Cases of cGvHD in First Allogeneic HSCT Cases, Men and Women, All Ages, 2018
Figure 14: 7MM, Age-Specific Diagnosed Incident Cases of aGvHD and cGvHD in First Allogeneic HSCT Cases, Men and Women, 2018
Figure 15: 7MM, Diagnosed Incident Cases of aGvHD by Grade, Men and Women, All Ages, 2018
Figure 16: 7MM, Diagnosed Incident Cases of cGvHD by Severity, Men and Women, All Ages, 2018
Figure 17: 7MM, 100-Day Mortality in Diagnosed Incident Cases of aGvHD, Men and Women, All Ages, 2018 and 2028
Figure 18: 7MM, One-Year Mortality in Diagnosed Incident Cases of cGvHD, Men and Women, All Ages, 2018
Figure 19: 7MM, Three-Year Diagnosed Prevalent Cases of aGvHD, Men and Women, All Ages, 2018
Figure 20: 7MM, Three-Year Diagnosed Prevalent Cases of cGvHD, Men and Women, All Ages, 2018
Filed in: Pharmaceutical
Publisher : GlobalData